Mark A Fiala1,2, Tanya M Wildes1. 1. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 2. George Warren Brown School of Social Work, Washington University, St. Louis, Missouri.
Abstract
BACKGROUND: Recent treatment advances have greatly improved the prognosis of patients with multiple myeloma. However, some of these newer, more effective treatments are intensive and expensive and their use remains low, particularly among black patients. METHODS: In the current study, the authors reviewed the use patterns of stem cell transplantation and bortezomib using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. RESULTS: After controlling for overall health and potential access barriers, black patients were found to be 37% (P<.0001) less likely to undergo stem cell transplantation, and 21% (P<.0001) less likely to be treated with bortezomib. Moreover, the authors found that the underuse of these treatments was associated with a 12% increase in the hazard ratio for death among black patients (P = 0.0007). CONCLUSIONS: Eliminating health disparities, a current focus of US public policy, is highly complex, as illustrated by the results of the current study. In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers. Additional factors, such as structural barriers in the health care system and individual decision making among black and white patients, must be explored to fully explain the disparity. Cancer 2017;123:1590-1596.
BACKGROUND: Recent treatment advances have greatly improved the prognosis of patients with multiple myeloma. However, some of these newer, more effective treatments are intensive and expensive and their use remains low, particularly among black patients. METHODS: In the current study, the authors reviewed the use patterns of stem cell transplantation and bortezomib using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. RESULTS: After controlling for overall health and potential access barriers, black patients were found to be 37% (P<.0001) less likely to undergo stem cell transplantation, and 21% (P<.0001) less likely to be treated with bortezomib. Moreover, the authors found that the underuse of these treatments was associated with a 12% increase in the hazard ratio for death among black patients (P = 0.0007). CONCLUSIONS: Eliminating health disparities, a current focus of US public policy, is highly complex, as illustrated by the results of the current study. In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers. Additional factors, such as structural barriers in the health care system and individual decision making among black and whitepatients, must be explored to fully explain the disparity. Cancer 2017;123:1590-1596.
Authors: Adam J Waxman; Pamela J Mink; Susan S Devesa; William F Anderson; Brendan M Weiss; Sigurdur Y Kristinsson; Katherine A McGlynn; Ola Landgren Journal: Blood Date: 2010-09-07 Impact factor: 22.113
Authors: Mark A Fiala; Joseph D Finney; Jingxia Liu; Keith E Stockerl-Goldstein; Michael H Tomasson; Ravi Vij; Tanya M Wildes Journal: Leuk Lymphoma Date: 2015-03-08
Authors: Mark A Fiala; Joseph D Finney; Keith E Stockerl-Goldstein; Michael H Tomasson; John F DiPersio; Ravi Vij; Tanya M Wildes Journal: Biol Blood Marrow Transplant Date: 2015-03-11 Impact factor: 5.742
Authors: A Ravindran; A C Bartley; S J Holton; W I Gonsalves; P Kapoor; M A Siddiqui; S K Hashmi; A L Marshall; A A Ashrani; A Dispenzieri; R A Kyle; S V Rajkumar; R S Go Journal: Blood Cancer J Date: 2016-10-21 Impact factor: 11.037
Authors: Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew Journal: Adv Cancer Res Date: 2019-04-23 Impact factor: 6.242
Authors: Jifang Zhou; Karen Sweiss; Edith A Nutescu; Jin Han; Pritesh R Patel; Naomi Y Ko; Todd A Lee; Brian C-H Chiu; Gregory S Calip Journal: JCO Oncol Pract Date: 2021-01-15